Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9713156 | 0.72 | ADORA3 (0.31) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL20907799 | 0.69 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL11459820 | 0.68 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL13129985 | 0.68 | CNR2 (0.31) | ALDH1A1 | |
| SCHEMBL24228122 | 0.63 | TSHR (0.43) | ALDH1A1HSP90AA1HSP90AB1 | |
| SCHEMBL6003419 | 0.63 | TSHR (0.43) | ALDH1A1HSP90AA1HSP90AB1 | |
| SCHEMBL1884589 | 0.62 | ALDH1A1 (0.34) | ALDH1A1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL4463921 | 0.61 | — | — | |
| SCHEMBL4104582 | 0.61 | — | — | |
| SCHEMBL367014 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020227020-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| US-10653681-B2 | Analgesic compounds | RECURIUM IP HOLDINGS, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190111031-A1 | ANALGESIC COMPOUNDS | KTHERA, LLC | 2019-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190111031-A1 | ANALGESIC COMPOUNDS | OPRK1, OPRL1, OPRM1 | ALDH1A1 113/4885ADORA3 371/4885ADORA2A 243/4885 |
| US-10653681-B2 | Analgesic compounds | OPRK1, OPRL1, OPRM1 | ALDH1A1 113/4885ADORA3 371/4885ADORA2A 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.